Gradalis Garners $24,000,000 Series B Financing

  • Feed Type
  • Date
    1/4/2013
  • Company Name
    Gradalis
  • Mailing Address
    2545 Golden Bear Drive Carrollton, TX 75006
  • Company Description
    Gradalis, Inc. is a fully integrated biotechnology company based in Dallas, Texas that focuses on the development, manufacturing, and commercialization of drugs, vaccines, tools, and diagnostics primarily in the area of cancer. Gradalis has its own GMP manufacturing facility along with highly skilled technical leadership and staff and a strategic partnership with Mary Crowley Cancer Research Centers for clinical development of Gradalis products.
  • Website
    http://www.gradalisinc.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $24,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Gradalis will use the funding to advance its autologous vaccine platform, FANG, through late-stage clinical trials and expand manufacturing capabilities to accommodate commercial launch of FANG. In addition, the funding will be used to progress the clinical and preclinical development of the company’s bifunctional shRNA platform.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy